Research Article

Identification of Target Genes Involved in the Antiproliferative Effect of Enzyme-Modified Ginseng Extract in HepG2 Hepatocarcinoma Cell

Sung-Il Jang,1 Yeon-Weol Lee,1 Chong-Kwan Cho,1 Hwa-Seung Yoo,1 and Jun-Hyeog Jang2

1 East-West Cancer Center, Dunsan Oriental Hospital of Daejeon University, Daejeon 302-122, Republic of Korea
2 Department of Biochemistry, Inha University School of Medicine, Incheon 400-712, Republic of Korea

Correspondence should be addressed to Hwa-Seung Yoo; altys@dju.kr and Jun-Hyeog Jang; juhjang@inha.ac.kr

Received 1 June 2013; Accepted 20 August 2013

Copyright © 2013 Sung-Il Jang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ginsenosides are ginseng saponins, which are the major biologically active components of Panax ginseng, often metabolized by intestinal bacteria into more effective forms. In this study, we found that the antiproliferative activity of ginseng increased after enzymatic processing of ginseng saponin (50% inhibitory concentration [IC50], >30 μg/mL), which may be the result of the accumulation of minor saponins, such as Rh1, Rg3, compound K, and PPT constituents in ginseng saponin. Using the Agilent PrimeView Human Gene Expression Array, we found that the expression of several genes involved in apoptosis (caspase-4, Annexin A2, HSPA9, AIFM1, UQCRC2, and caspase-7) were increased in HepG2 human hepatocarcinoma cells after their treatment with enzyme-modified ginseng extract (EMGE). Furthermore, several genes implicated in cell cycle progression (CDCA3, CDCA8, CABLES2, CDC25B, CNNM3, and CCNK) showed decreased expression in HepG2 cells treated with EMGE. Finally, from flow cytometric analysis, we found that EMGE-treated HepG2 cells showed increased apoptotic sub-G1 population (24%), compared with that observed in DMSO-treated control cells (1.6%). Taken together, our results suggest that EMGE induces anticancer activity through the induction of apoptosis-related genes and cell cycle arrest via decreased expression of cell cycle regulatory genes.

1. Introduction

Panax ginseng (Korean ginseng) has been used as a traditional medicine for the treatment of cancer and has been shown to inhibit tumor cell proliferation and tumor growth, to induce differentiation and apoptosis, and to inhibit cancer cell invasion [1–4]. The major biologically active components of Panax ginseng are a series of saponin glycosides collectively known as the ginsenosides, a group of steroidal saponins. Over 50 ginsenosides have been isolated and identified from ginseng saponins to date [5].

Ginsenosides are characterized by a steroid-like skeleton consisting of 4 trans-rings, with modifications that depend on the type (e.g., glucose, maltose, and fructose) and number of sugar moieties, as well as the sites of attachment of the hydroxyl group (e.g., C-3, C-6, or C-20). Based on chemical structural characteristics, ginseng saponins can be divided into protopanaxadiol and protopanaxatriol groups, except for ginsenoside Ro, which is derived from an oleanolic group. In the protopanaxadiol group, sugars are attached to the β-OH at C-3 and another –OH at C-20, as found in Rh1, Rb2, Rc, Rd, Rg3, and Rh2. In the protopanaxatriol group, sugar residues are attached to the α-OH at C-6, with another –OH at C-20, examples being Re, Rgl, Rg2, Rh1, and Rf.

Recent studies have indicated that intestinal bacteria cleave the oligosaccharide connected to the aglycon stepwise from the terminal sugar to form the ginsenoside metabolite 20S-protopanaxadiol 20-O-β-D-glucopyranoside (compound K) after oral administration of ginseng extract in both humans and rats [6]. Wakabayashi et al. have revealed that the antitumor activities of ginsenoside following oral administration are attributable to the metabolites formed by colonic bacteria-mediated deglycosylation [7]. In addition, compound K is known to exhibit cytotoxicity by the induction of apoptosis and cell cycle arrest at the G1 phase, by a caspase-dependent pathway via mitochondrial disruption in
tumor cells, and by reversing multidrug resistance in tumor cells [8–10]. The combined treatment of compound K and radiation enhances human lung cancer cell death [8, 11].

Various transformation methods, including mild acid hydrolysis, enzymatic conversion, and microbial conversion, have been tested for their ability to transform ginsenosides to enhance their physiological effectiveness. In this study, we investigated the antiproliferative effects and possible mechanism of action of EMGE that were transformed by enzyme treatment, by using the human hepatocarcinoma cell line HepG2.

2. Materials and Methods

2.1. Cell Culture. HepG2 cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (Invitrogen, Carlsbad, CA), 100 units/mL penicillin G sodium, 100 μg/mL streptomycin sulfate, and 0.25 μg/mL amphotericin B (Invitrogen, Carlsbad, CA) in a 5% CO₂ atmosphere at 37°C. Confluent cells were detached with 0.25% trypsin-EDTA for 5 min, and aliquots were subcultured. Human hepatoma HepG2 cells were purchased from the Korean Cell Line Bank (KCLB, Seoul, Republic of Korea).

2.2. Preparation of Enzyme-Modified Ginseng Extract (EMGE). The root of regular ginseng (4 years old) was purchased from G&V, Korea. A total of 20 g of pulverized ginseng root powder were suspended in 380 mL of distilled water and then sterilized by heating at 121°C for 15 min. To reduce the complexity of components in ginseng root, the extract was fractionated via extraction with water, methanol, and butanol. Among the fractions, ginseng butanol extract contained the compounds with specific anticancer activity. In addition, the suspension was treated with aliquots of filter-sterilized commercial enzymes (laminarinase 100 mg, pectinase 100 mg) with an equimolar ratio (1:1, specific activity unit). For these treatments, the mixture was incubated at 40°C for 2 days and then evaporated to dryness at 60°C. These enzyme-modified ginseng powders were then suspended in 400 mL of 80% (v/v) methanol and subjected to ultrasonication for 5 min followed by filtration through Whatman No. 2 Filter Paper. The wet powder on the filter paper was then collected, suspended, treated in an ultrasound bath, and filtered in the same manner once again, after which the two filtrates were combined and evaporated to dryness at 50°C. The methanol extract dissolved in 200 mL of distilled water was washed with 200 mL of ethyl acetate in a separation funnel and then extracted with 200 mL of butanol. Next, the butanol extract was evaporated to dryness at 50°C and then dissolved to a concentration of 10% (w/v) in 70% ethanol.

2.3. HPLC Analysis of Ginsenosides. Standard ginsenosides including Rgl, Re, Rf, Rh1, Rbl, Rc, Rb2, f1, Rd, Rg3(S), Rg3(R), PPT, Com K, Rh2, and PPD were obtained from ChromaDex Inc. (Irvine, CA) and analyzed using an Acquity UPLC system (Waters, Milford, MA) with an Acquity BEH C₁₈ HPLC column. The mobile phase consisted of solution A (CH₃CN, HPLC-grade, JT Baker, NJ) and solution B (Milli-Q H₂O, Millipore, MA). The flow rate was set at 0.6 mL/min, and the injection of volume was fixed at 2:1. The separation of ginsenosides was performed using an isocratic gradient of 100% solution A for 27 min. The column temperature was maintained at room temperature during the separation, and the UV diode array detection was set at 203 nm. To confirm a reliable retention time of sample ginsenoside, the individual ginsenosides were identified and quantified based on comparison with the retention times of standard ginsenosides.

2.4. Cell Viability Assay. The effect of EMGE on cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, a yellow tetrazole) assay, which quantifies the number of viable cells. Cells were seeded (2 × 10⁴ cells/well) in 24-well flat-bottomed plates (Nunc, EU). After incubation at 37°C for 24 h, the medium was replaced with EMGE at the appropriate concentrations. Control cells were treated with DMSO at a final concentration of less than 0.2%. After further 24 h incubation, cells were washed 3 times with Dulbecco’s phosphate-buffered saline (DPBS), and 500 μL MTT solution (5 mg/mL in PBS) was added to each well. After incubating for 4 h, the medium was removed, and 200 μL of formazan (crystals dissolved in DMSO) was added to the cells. The absorbance of each well was read at 540 nm using a microplate reader.

2.5. RNA Extraction and cDNA Synthesis. Total RNA was extracted using the Easy-spin RNA Extraction kit (iNtRON, Seoul, Republic of Korea) according to the manufacturer’s instructions. The purity of RNA was assessed by measuring the absorption at 260 and 280 nm (values of the ratio of A260/A280 of 1.9–2.1 were considered acceptable) and by ethidium bromide staining of 18S and 28S RNA by gel electrophoresis. RNA concentrations were determined from the A260. Two micrograms of total RNA were reverse-transcribed in a 20 μL reaction mixture containing 50 units of SuperScript II reverse transcriptase (Invitrogen, Carlsbad, CA), 5 μM DTT, 40 units of RNaseOUT recombinant ribonuclease inhibitor (Invitrogen, Carlsbad, CA), 0.5 μM of random hexanucleotide primers, and 500 μM of dNTP mixture. The reverse transcription reaction was carried out at 50°C for 60 min. The reaction was terminated by heating the reaction mixture at 70°C for 15 min, and the cDNA was stored at −20°C.

2.6. Quantitative Real-Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). Overexpression of the target genes was confirmed by quantitative real-time RT-PCR. All real-time PCR analyses were performed on an ABI Step One Real-time PCR system (Applied Biosystems). Each reaction contained 0.1 μM of each primer, 10 μL of 2x SYBR Green PCR master mix (including AmpliTaq Gold DNA polymerase with buffer, dNTPs mix, SYBR Green I dye, ROX dye, and 10 mm MgCl₂, Applied Biosystems), and 1 μL of the template cDNA in a 20 μL total reaction volume. The typical
amplification program included activation of the enzyme at 94°C for 10 min, followed by 40 cycles of denaturation at 94°C for 15 s, then annealing and extension at 60° C for 1 min. The C_T (cycle threshold) value for each gene was determined using the automated threshold analysis function of the ABI instrument and normalizing to C_T(G3PDH) to obtain ΔC_T (C_T(G3PDH) − C_T(test)). The difference of n between the 2C_T or ΔC_T values indicates a 2^n-fold difference in the amount of the target sequence between the 2 cDNA samples being compared. The primers used in quantitative PCR are shown in Table 1.

### 2.7. Microarray Assay

Gene expression was analyzed with Agilent PrimeView Human Gene Expression Array containing 36,000 probe sets representing approximately 38,500 well-characterized human genes. For each gene, 11 pairs of oligonucleotide probes were synthesized in situ on the arrays. Biotinylated cRNA was prepared according to the standard Affymetrix protocol from 100 ng of total RNA (Expression Biotinylated cRNA was prepared according to the standard Affymetrix protocol from 100 ng of total RNA (Expression Biotinylated cRNA was prepared according to the standard Affymetrix protocol from 100 ng of total RNA (Expression Biotinylated cRNA was prepared according to the standard Affymetrix protocol from 100 ng of total RNA (Expression Biotinylated cRNA was prepared according to the standard Affymetrix protocol from 100 ng of total RNA (Expression Biotinylated cRNA was prepared according to the standard Affymetrix protocol from 100 ng of total RNA (Expression Biotinylated cRNA was prepared according to the standard Affymetrix protocol from 100 ng of total RNA (Expression Biotinylated cRNA was prepared according to the standard Affymetrix protocol from 100 ng of total RNA (Expression Biotinylated cRNA was prepared according to the standard Affymetrix protocol from 100 ng of total RNA (Expression Biotinylated cRNA was prepared according to the standard Affymetrix protocol from 100 ng of total RNA (Expression Biotinylated cRNA was prepared according to the standard Affymetrix protocol from 100 ng of total RNA (Expression Biotinylated cRNA was prepared according to the standard Affymetrix protocol from 100 ng of total RNA (Expression Biotinylated cRNA was prepared according to the standard Affymetrix protocol from 100 ng of total RNA (Expression Biotinylated cRNA was prepared according to the standard Affymetrix protocol to 100 ng of total RNA using the T7 transcription kit (Affymetrix, Santa Clara, CA). The labeled cRNA was then washed and stained in the Affymetrix Fluidics Station 450. GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G. The data were analyzed with Microarray Suite version 5.0 using the Affymetrix default analysis settings and global scaling as the normalization method. The trimmed mean target intensity of each array was arbitrarily set to 100. Normalized and log transformed intensity values were then analyzed using GeneSpring GX 11.5.1 (Agilent Technologies, CA). Fold-change filters included the requirement that the genes be present in at least 200% of controls for genes with upregulated expression and less than 50% of controls for genes with downregulated expression. Hierarchical cluster analysis using GeneSpring GX 11.5.1 (Agilent Technologies, CA) identified clustered groups as those that behaved similarly across experiments. The clustering algorithm was Euclidean distance, with average linkage.

#### 2.8. Cell Count and Flow Cytometry Analysis

Cell counts were performed using a hemocytometer. Approximately 1 × 10^6 HepG2 cells were suspended in 100 μL of PBS, and 200 μL of 95% ethanol was added while vortexing. The cells were incubated at 4°C for 1 h, washed with PBS, and resuspended in 250 μL of 1.12% sodium citrate buffer (pH 8.4) together with 12.5 μg of RNase. Incubation was continued at 37°C for 30 min. The cellular DNA was then stained by applying 250 μL of propidium iodide (50 μg/mL) for 30 min at room temperature. The stained cells were analyzed by fluorescence-activated cell sorting (FACS) flow cytometry (FACScanner, Becton Dickinson) for relative DNA content based on red fluorescence.

### 3. Results

#### 3.1. Chromatographic Analysis of Ginseng Saponin during the Enzyme Treatment

Ginseng saponins (ginsenosides) have been regarded as the principal components responsible for the pharmacological activities of ginseng, and a large number of ginsenoside derivatives have been identified in *Panax ginseng* [5]. Recently, cytotoxic effects of minor saponins, such as Rh1 and Rh2, on the growth of various cancer cells and also inhibitory effects of human intestinal bacterial saponin metabolites, such as compound K and protopanaxatriol (PPT), on the growth, invasion, and migration of tumor cells, have been reported [12–16]. High-performance liquid chromatography (HPLC) analysis was performed to determine the changes in chemical constituent in ginseng saponin following enzyme treatment. HPLC results showed the appearance of minor ginsenosides (Rh1, Rg3, and compound K), indicative of EMGE (Table 2).

#### 3.2. Antiproliferative Effects of EMGE on HepG2 Hepatocarcinoma Cells

Ginsenosides have been shown to inhibit tumor cell proliferation and tumor growth and to induce differentiation and apoptosis [17]. To determine the antiproliferative effects of EMGE on HepG2 human hepatocarcinoma cells, we performed the MTT assay. EMGE inhibited HepG2 cell growth in a dose-dependent manner at 14.8, 22.2, 33.3, 50, and

---

### Table 1: Primer sequences for real-time RT-PCR experiments.

| Genes       | Sense (5’-3’)       | Antisense (5’-3’)          |
|-------------|---------------------|-----------------------------|
| Caspase-4   | GAAGGACAAACCCCAAGGTCA | AAGAGGCCACTTTCCAAGGAT       |
| Cyp450      | TGATAAGCAGGTGCGAGAG  | CAAAGCAAATGGCAGAGATG        |
| Caspase-7   | AGACCTCATTCCGTCAGT    | TTATCACAGACGCGCAACGC        |
| Cyclin M    | GAAGCGGAGGAGGTCTTCT   | CGGCGCTAATACATCCCTT         |
| Cyclin K    | GACATCTGGCAGCAAATCCT  | GCACGTGTGGTGTAGGCTGA         |
| GAPDH       | TGGAAGGACTCATGACCACA  | TTCAGCTCAGGGGATAGCCCTT      |

### Table 2: HPLC analysis of EMGE.

|          | Rgl | Re  | Rf  | Rhl | Rb1 | Rc  | Rb2 | F1  | Rd  | Rg3 | Com.K | Rh2 |
|----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|-----|
| Control  | 9.2 | 7.2 | 2.5 | —   | 7.7 | 4.7 | 2.3 | 2.0 | 0.6 | —   | —     | —   |
| EMGE     | 0.6 | 1.0 | 2.5 | —   | 2.7 | 2.7 | —   | —   | —   | 9.5 | 4.7   | 2.7  |
Table 3: Genes with highly upregulated expression due to EMGE in HepG2.

| Symbol | Gene description                  | Fold change | GenBank ID        |
|--------|-----------------------------------|-------------|-------------------|
| CYP1A1 | Cytochrome P450, family 1, subfamily A | 20.0        | NM000499          |
| HGD    | Homogentisate 1,2-dioxygenase      | 15.3        | NM000187          |
| AQG3   | Aquaporin 3                        | 14.5        | NM004925          |
| IL8    | Interleukin 8                      | 14.3        | NM000584          |
| ANXA2  | Annexin A2                         | 11.1        | NM00102857        |
| HSPA9  | Heat shock 70 kDa protein 9         | 10.5        | NM004134          |
| CASP4  | Caspase-4                           | 10.4        | NM001225          |
| SMAD2  | SMAD family member 2                | 9.8         | NM00103652        |
| MAPK6  | Mitogen-activated protein kinase 6  | 9.3         | NM002748          |
| KLF6   | Kruppel-like factor 6               | 9.0         | NM001160124       |
| CTNNB1 | Catenin (cadherin-associated protein), beta 1, 88 kda | 8.3         | NM001098209       |
| AIFM1  | Apoptosis-inducing factor, mitochondrial- associated, 1 | 7.8         | NM00130846        |
| PPHLN1 | Periphalin 1                        | 7.5         | NM00143787        |
| UQCRCC2| Ubiquinol-cytochrome c reductase core protein II | 7.4         | NM003366          |
| IL6ST  | Interleukin 6 signal transducer     | 6.4         | NM00190981        |
| IFITM1 | Interferon-induced transmembrane protein 1 | 5.1         | NM003641          |
| CASP7  | Caspase-7                           | 5.0         | NM001227          |

Figure 1: Antiproliferative effects of EMGE on human HepG2 hepatocarcinoma cells. Cell viability at the indicated concentrations of EMGE at 24 h was assessed by the MTT test. The treated cells were used for total RNA isolation followed by microarray analysis.

100 µg/mL at 24 h. The concentration at which 50% growth inhibition (IC50) occurred was 30 µg/mL (Figure 1). However, exposure of HepG2 cells to 30 µg/mL nontreated ginseng saponin extract showed less growth inhibition (approximately 20%). Thus, these results suggest that enzymatic processing of ginseng saponin increased its antiproliferative effects on HepG2 cells.

3.3. Identification of Differentially Expressed Genes in HepG2 Human Hepatocarcinoma Cells Treated with EMGE. Although ginseng has been used as a traditional medicine for the treatment of cancer, the underlying mechanisms for the varying activities observed following exposure to ginseng are largely unclear. To identify relevant alterations of gene expression associated with treatment of EMGE, we analyzed the gene expression profiles of HepG2 cells by using Affymetrix Gene Chip arrays containing more than 38,500 genes. From the results of Affymetrix Gene Chip array analysis, we detected 31 differentially expressed genes exhibiting at least a 5-fold change following treatment with EMGE. Of these, 17 had significantly upregulated expression, and 14 had significantly downregulated expression when comparing treatment with the EMGE versus the control treatment (Tables 3 and 4).

Several genes involved in apoptosis (caspase-4, Annexin A2, HSPA9, AIFM1, UQCRCC2, and caspase-7) were expressed at higher levels following treatment with EMGE. Furthermore, several genes implicated in cell adhesion (CTNNB1), transport (AQG3, IFITM1), and the immune response (IL8) showed increased expression in HepG2 human hepatocarcinoma cells that were treated with EMGE.

In contrast, 14 genes showed reduced expression in HepG2 human hepatocarcinoma cells treated with EMGE. There was an overrepresentation of members of genes involved in cell cycle progression (CDCA3, CDCA8, CABLES2, CDC25B, CNMN3, and CCNK) and cellular metabolism (CS, ALDH3B1, and NPRL3). Table 4 lists the names of genes exhibiting a reduction in expression, where the difference was >5-fold. This group of genes that were expressed very differently may serve as an important target in EMGE-mediated anticancer activity in human hepatocarcinoma cells.

3.4. Real-Time RT-PCR Validation of Microarray Data. To confirm the results obtained using microarrays, we choose to determine if the expression of 5 target genes was regulated by EMGE in HepG2 cells by quantitative real-time RT-PCR analysis. These genes included 3 genes with highly upregulated expression (cyp450, caspase-4, and caspase-7)
and 2 with highly downregulated expression (Cyclin K and Cyclin M). To accurately quantify the expression of these 5 genes, GAPDH expression was amplified and the mean data in each case was used to normalize the result.

As shown in Figures 2 and 3, the expression level of the 3 selected upregulated genes (cyp450 (73-fold), caspase-4 (6-fold), and caspase-7 (3-fold)) significantly increased upon treatment with EMGE. Conversely, the expression of the 2 downregulated genes (Cyclin M (4-fold), Cyclin K (12-fold)) decreased. These results indicate that the real-time RT-PCR results are highly consistent with the microarray data.

### 3.5. Effect of EMGE on Cell Cycle Distribution and Apoptosis in HepG2 Hepatocarcinoma Cells

To determine whether EMGE has an effect on cell cycle arrest, apoptosis, or both in human HepG2 hepatocarcinoma cells, cells treated with DMSO or EMGE for 12 or 24 h were subjected to flow cytometric analysis after DNA staining. Histograms of flow cytometric data are shown in Figure 4. Control cells (DMSO-treated) progressed through the cell cycle normally. In contrast, EMGE-treated HepG2 cells showed increased apoptotic sub-G1 populations (24%) compared with that observed in DMSO-treated control cells (1.6%). These results suggest that EMGE induces antiproliferative effects in HepG2 cells, mainly through apoptotic mechanisms.

### 4. Discussion

We found that the enzymatic processing of ginseng saponin could increase the content of active constituents and enhance its anticancer activity, presumably because of the production of minor saponins, such as Rh1, Rg3, compound K, and PPT constituents in ginseng saponin. In this study, we used cDNA microarray analysis to detect target genes involved in the anticancer activity of EMGE. Microarray (DNA chip) is a 2D array of microscopic DNA spots for high-throughput expression screening. We found that several genes involved in apoptosis (caspase-4, Annexin A2, HSPA9, AIFM1, UQCRGC2, and caspase-7) as well as several genes involved in cell signaling (MAPK6, SMAD2, IL6ST, KLF6, and IFITM1) were expressed at higher levels after treatment with EMGE. Furthermore, several genes implicated in cell cycle progression (CDCA3, CDCA8, CABLES2, CDC25B, CNNM3, and CCNK) and metabolism (CS, ALDH3B1, and NPRL3) exhibited decreased expression in HepG2 human hepatocarcinoma cells treated with EMGE. Thus, the apoptosis-related genes with upregulated expression and cell cycle-related genes with downregulated expression could be important target genes involved in the anticancer activity of EMGE.

In this study, caspase-4 and caspase-7, which are components of the cell-intrinsic apoptosis machinery, were significantly induced by EMGE. Caspase-4 has a functional role in endoplasmic-reticulum-stress- (ERS-) induced apoptosis in humans [18]. Upregulation of caspase-4 has been demonstrated to mediate apoptosis in human bronchial epithelial cells [19], human neuroblastoma SKN-SH cells, and human esophageal squamous carcinoma EC109 [20]. Thus, the induction of apoptosis-related genes, such as caspase-4 and caspase-7, in cells treated with EMGE may contribute to the antiproliferative activity of EMGE.

The cytochrome P450 1A1 (CYP1A1) is a member of the cytochrome P450 monooxygenase superfamily, which plays an important role in xenobiotic metabolism as well as in carcinogenesis [21]. In this study, CYP1A1 level was significantly increased after treatment with EMGE. The CYP1A1 enzymes mediate the bioactivation of carcinogens found both in the human diet and in the environment, including compounds such as polycyclic aromatic hydrocarbons, such as 3-methylcholanthrene, benzo(a)pyrene, polyhalogenated aromatic hydrocarbons, and certain congeners of polyhalogenated biphenyls [22]. Our finding that the EMGE increased the expression of CYP1A1 is consistent with the previous results showing the induction of CYP1A1 expression by ginsenosides Rgl and Rbt [23].

Cell cycle progression is a tightly regulated process requiring regulatory factors such as CDCs and cyclins. Thus, lack of cell cycle machinery molecules often causes cell cycle arrest leading to cell growth inhibition, apoptosis, or both.
Our results showing the decreased expression of several genes implicated in cell cycle regulation (CDCA3, CDCA8, CABLES2, CDC25B, CNNM3, and CCNK) in HepG2 cells treated with EMGE suggest that the induction of cell cycle arrest by EMGE may contribute to the antiproliferative activity of EMGE.

In summary, we found that the anticancer activity of ginseng was increased by enzymatic processing of ginseng
saponin, which may be the result of the relative accumulation of minor saponins, such as Rh1, Rg3, compound K, and PPT constituents in ginseng saponin. Moreover, the results of microarray analysis suggest that EMGE induces anticancer activity through the induction of apoptosis-related genes and the decreased expression of cell cycle regulatory genes. However, these results do not exclude the role of other genes that may be involved in anticancer activity.

Acknowledgments

This work was supported by the National Research Foundation Korea (NRF) Grant funded by the Korean Government (MOE) (2010-0022628, 2013R1A1A201375) and Inha University Grant.

References

[1] I. S. An, S. An, K. J. Kwon, Y. J. Kim, and S. Bae, “Ginsenoside Rh2 mediates changes in the microRNA expression profile of human non-small cell lung cancer A549 cells,” Oncology Reports, vol. 29, no. 2, pp. 523–528, 2013.

[2] A. D. Kim, K. A. Kang, R. Zhang et al., “Ginseng saponin metabolite induces apoptosis in MCF-7 breast cancer cells through the modulation of AMP-activated protein kinase,” Environmental Toxicology and Pharmacology, vol. 30, no. 2, pp. 134–140, 2010.

[3] H. Yuan, H. Quan, Y. Zhang, S. H. Kim, and S. Chung, “20(S)-ginsenoside Rg3-induced apoptosis in HT-29 colon cancer cells is associated with AMPK signaling pathway,” Molecular Medicine Reports, vol. 3, no. 5, pp. 825–831, 2010.

[4] X. Pan, H. Guo, J. Han et al., “Ginsenoside Rg3 attenuates cell migration via inhibition of aquaporin 1 expression in PC-3M prostate cancer cells,” European Journal of Pharmacology, vol. 683, no. 1–3, pp. 27–34, 2012.

[5] O. Tanaka and R. Kasai, “Saponins of ginseng and related plants,” Fortschritte der Chemie Organischer Naturstoffe, vol. 46, pp. 1–76, 1984.

[6] H. Hasegawa, J. Sung, S. Matsumiya, and M. Uchiyama, “Main ginseng saponin metabolites formed by intestinal bacteria,” Planta Medica, vol. 62, no. 5, pp. 453–457, 1996.

[7] C. Wakabayashi, H. Hasegawa, J. Murata, and I. Saiki, “In vivo antimetastatic action of ginseng protopanaxadiol saponins is based on their intestinal bacterial metabolites after oral administration,” Oncology Research, vol. 9, no. 8, pp. 411–417, 1997.

[8] K. A. Kang, Y. W. Kim, S. U. Kim et al., “G1 phase arrest of the cell cycle by a ginseng metabolite, compound K, in U937 human monocytic leukemia cells,” Archives of Pharmacal Research, vol. 28, no. 6, pp. 685–690, 2005.

[9] H. Hasegawa, S. Matsumiya, M. Uchiyama et al., “Inhibitory effect of some triterpenoid saponins on glucose transport in tumor cells and its application to in vitro cytotoxic and antiviral activities,” Planta Medica, vol. 60, no. 3, pp. 240–243, 1994.

[10] B. H. Lee, S. J. Lee, J. H. Hur et al., “In vitro antigenotoxic activity of novel ginseng saponin metabolites formed by intestinal bacteria,” Planta Medica, vol. 64, no. 6, pp. 500–503, 1998.

[11] S. Chae, K. A. Kang, W. Y. Chang et al., “Effect of compound K, a metabolite of ginseng saponin, combined with γ-ray radiation in human lung cancer cells in vitro and in vivo,” Journal of Agricultural and Food Chemistry, vol. 57, no. 13, pp. 5777–5782, 2009.

[12] E. Bae, M. J. Han, M. Choo, S. Park, and D. Kim, “Metabolism of 20(S)- and 20(R)-ginsenoside Rg3 by human intestinal bacteria and its relation to in vitro biological activities,” Biological & Pharmaceutical Bulletin, vol. 25, no. 1, pp. 58–63, 2002.

[13] S. Lee, J. Sung, S. Lee, C. Moon, and B. Lee, “Antitumor activity of a novel ginseng saponin metabolite in human pulmonary adenocarcinoma cells resistant to cisplatin,” Cancer Letters, vol. 144, no. 1, pp. 39–43, 1999.

[14] S. Odashima, T. Ohta, and H. Kohno, “Control of phenotypic expression of cultured B16 melanoma cells by plant glycosides,” Cancer Research, vol. 45, no. 6, pp. 2781–2784, 1985.

[15] J. A. Park, K. Y. Lee, Y. J. Oh, K. Kim, and S. K. Lee, “Activation of caspase-3 protease via a Bel-2-insensitive pathway during the process of ginsenoside Rh2-induced apoptosis,” Cancer Letters, vol. 121, no. 1, pp. 73–81, 1997.
[16] C. Wakabayashi, K. Murakami, H. Hasegawa, J. Murata, and I. Saiki, "An intestinal bacterial metabolite of ginseng protopanaxadiol saponins has the ability to induce apoptosis in tumor cells," *Biochemical and Biophysical Research Communications*, vol. 246, no. 3, pp. 725–730, 1998.

[17] T. K. Yun, Y. S. Lee, Y. H. Lee, S. I. Kim, and H. Y. Yun, "Anticarcinogenic effect of *Panax ginseng* C.A. Meyer and identification of active compounds," *Journal of Korean Medical Science*, vol. 16, pp. S6–S18, 2001.

[18] J. Hitomi, T. Katayama, Y. Eguchi et al., "Involvement of caspase-4 in endoplasmic reticulum stress-induced apoptosis and Aβ-induced cell death," *Journal of Cell Biology*, vol. 165, no. 3, pp. 347–356, 2004.

[19] Y. Tagawa, N. Hiramatsu, A. Kasai et al., "Induction of apoptosis by cigarette smoke via ROS-dependent endoplasmic reticulum stress and CCAAT/enhancer-binding protein-homologous protein (CHOP)," *Free Radical Biology and Medicine*, vol. 45, no. 1, pp. 50–59, 2008.

[20] B. Liang, X. Song, G. Liu et al., "Involvement of TR3/Nur77 translocation to the endoplasmic reticulum in ER stress-induced apoptosis," *Experimental Cell Research*, vol. 313, no. 13, pp. 2833–2844, 2007.

[21] F. J. Gonzalez and H. V. Gelboin, "Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins," *Drug Metabolism Reviews*, vol. 26, no. 1-2, pp. 165–183, 1994.

[22] M. S. Denison and S. R. Nagy, "Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals," *Annual Review of Pharmacology and Toxicology*, vol. 43, pp. 309–334, 2003.

[23] Y. Wang, X. Ye, Z. Ma et al., "Induction of cytochrome P450 1A1 expression by ginsenoside Rgl and Rbl in HepG2 cells," *European Journal of Pharmacology*, vol. 601, no. 1–3, pp. 73–78, 2008.